Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 28, 2015
EISAI COMPLETES ACQUISITION OF CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.
December 18, 2015
Notice Regarding Succession of Business of Consolidated Pharmaceutical Manufacturing and Marketing Subsidiary Sannova
December 11, 2015
MHLW APPROVES PARTIAL LABEL CHANGE FOR EGG-WHITE LYSOZYME PREPARATION NEUZYM®
December 2, 2015
EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) AT 69TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 1, 2015
EISAI AND TOYAMA CHEMICAL CLEAR ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTIRHEUMATIC AGENT IGURATIMOD (BRAND NAMES: CARERAM® TABLETS 25 MG/KOLBET® TABLETS 25 MG)
December 1, 2015
U.S. FDA ACCEPTS NDA FOR ONCE-DAILY FORMULATION OF ANTIOBESITY AGENT BELVIQ®
November 27, 2015
EISAI TO ACQUIRE CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.
STRENGTHENING BUSINESS PLATFORM IN CHINA TO ADDRESS DIVERSE MEDICAL NEEDS
November 26, 2015
Notice Regarding Transfer of Shares in Eisai Subsidiary
November 20, 2015
Notice Regarding Transfer of Shares Involving Changes in Eisai Subsidiary
November 20, 2015
EISAI LICENSES SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR E6005 TO ROIVANT SCIENCES
November 17, 2015
SUCCESSFUL RULING IN PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES
November 5, 2015
EISAI TO COMMENCE TWO JOINT RESEARCH PROGRAMS TOWARD DEVELOPMENT OF NEW ANTIMALARIAL MEDICINES
PARTNERSHIPS WITH LIVERPOOL SCHOOL OF TROPICAL MEDICINE / UNIVERSITY OF LIVERPOOL AND MEDICINES FOR MALARIA VENTURE
November 2, 2015
EISAI PRESENTS RESULTS FROM PHASE Ⅲ TRIAL OF ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL-ONSET SEIZURES CONDUCTED IN ASIA INCLUDING JAPAN
ORAL PRESENTATION GIVEN AT 49TH CONGRESS OF THE JAPAN EPILEPSY SOCIETY
October 19, 2015
PHASE Ⅱ TRIAL RESULTS ON NOVEL ANTICANCER AGENT LENVIMA® IN RENAL CELL CARCINOMA PUBLISHED IN THE LANCET ONCOLOGY
October 15, 2015
AGREEMENT CONCERNING THE INTEGRATION OF THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND AJINOMOTO PHARMACEUTICALS CO., LTD. BY ABSORPTION-TYPE SPLIT
Aiming to become Japan's Largest Gastrointestinal Specialty Pharma
October 9, 2015
EISAI RECEIVES APPROVAL FOR ANTICANCER AGENT LENVIMA® IN SOUTH KOREA
October 5, 2015
EISAI TO PROVIDE DIETHYLCARBAMAZINE CITRATE TABLETS FREE OF CHARGE FOR USE IN NATIONAL LYMPHATIC FILARIASIS ELIMINATION CAMPAIGN IN INDONESIA
September 30, 2015
Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
September 29, 2015
EISAI RECEIVES ADDITIONAL APPROVAL IN JAPAN FOR VASCULAR EMBOLIZATION DEVICE DC BEAD® AS TREATMENT OF HYPERVASCULAR TUMORS AND ARTERIOVENOUS MALFORMATIONS
To be Applicable for Insurance Reimbursement Once Listing Procedures are Completed
September 29, 2015
U.S. FDA GRANTS PRIORITY REVIEW STATUS TO sNDA FOR ANTICANCER AGENT HALAVEN® AS TREATMENT FOR SOFT TISSUE SARCOMA
September 25, 2015
EISAI TO SPONSOR LECTURES AT JAPAN RESEARCH CENTER OF FUDAN UNIVERSITY IN CHINA
TO PROMOTE FURTHER UNDERSTANDING BETWEEN CHINA AND JAPAN AS WELL AS ADVANCE CULTURAL EXCHANGE
September 17, 2015
EISAI SELECTED FOR THIRD CONSECUTIVE YEAR OF MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2015
September 14, 2015
EISAI TO PRESENT LATEST CLINICAL DATA ON LENVIMA® (LENVATINIB) AND HALAVEN® (ERIBULIN) AT EUROPEAN CANCER CONGRESS
September 10, 2015
Drugs for Neglected Diseases initiative and 缅北禁地. to Test Drug Candidate for Eumycetoma
Patients suffering from virtually no R&D for this neglected disease
September 10, 2015
LAUNCH OF NEW KL-6 DIAGNOSTIC KIT HISCL KL-6, FOR DETECTING MARKER FOR INTERSTITIAL PNEUMONIA WITH HISCL AUTOMATED IMMUNOASSAY SYSTEMS
September 2, 2015
EISAI CLEARS ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTICANCER DRUG GLIADEL® 7.7MG IMPLANT
August 31, 2015
EISAI INC. AND PURDUE PHARMA ENTER WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE LEMBOREXANT
Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications
August 5, 2015
EISAI LISTED FOR 14TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
July 31, 2015
EISAI AND HALOZYME SIGN COLLABORATION AGREEMENT TO INVESTIGATE ERIBULIN AND PEGPH20 IN ADVANCED BREAST CANCER
July 31, 2015
CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 30, 2015
EISAI SUBMITS APPLICATIONS FOR ANTICANCER AGENT HALAVEN® SIMULTANEOUSLY IN JAPAN, U.S. AND EUROPE SEEKING NEW INDICATION AS TREATMENT FOR SOFT TISSUE SARCOMA
July 29, 2015
EISAI'S IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM U.S. FDA FOR RENAL CELL CARCINOMA
July 27, 2015
EISAI SUBMITS NEW DRUG APPLICATION IN JAPAN FOR IN-HOUSE-DISCOVERED ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES
July 21, 2015
JCR AND EISAI CONCLUDE FEASIBILITY STUDY AGREEMENT ON APPLICATION OF BLOOD-BRAIN-BARRIER PENETRATION TECHNOLOGY TO DISCOVER NEW TREATMENTS
July 16, 2015
EISAI ENTERS AGREEMENT TO TRANSFER NORTH CAROLINA PLANT IN THE U.S. TO BIOGEN
July 15, 2015
LAUNCH OF STACIA CLEIA PIVKA-Ⅱ EISAI DIAGNOSTIC KIT FOR DETECTING HEPATOCELLULAR CARCINOMA TUMOR MARKER WITH AUTOMATED IMMUNOANALYZER
June 26, 2015
EISAI TO LAUNCH NEW FINE GRANULE FORMULATION OF TACHYARRHYTHMIA TREATMENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS IN JAPAN
June 25, 2015
EUROPEAN COMMISSION APPROVES INDICATION EXPANSION OF EISAI鈥橲 ANTIEPILEPTIC AGENT FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 22, 2015
U.S. FDA APPROVES EISAI鈥橲 ANTIEPILEPTIC AGENT FYCOMPA® AS ADJUNCTIVE TREATMENT FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 10, 2015
EISAI LAUNCHES ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) IN UNITED KINGDOM INDICATED FOR ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
June 1, 2015
PHASE Ⅱ TRIAL RESULTS ON ANTICANCER AGENT LENVIMA® IN RENAL CELL CARCINOMA TO BE DETAILED IN ORAL PRESENTATION AT 51ST ASCO ANNUAL MEETING
COMBINATION THERAPY WITH EVEROLIMUS DEMONSTRATES SIGNIFICANT EXTENSION IN PROGRESSION-FREE SURVIVAL
June 1, 2015
EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
May 30, 2015
ANTICANCER AGENT HALAVEN® SHOWS SIGNIFICANT EXTENSION IN OVERALL SURVIVAL IN PHASE Ⅲ STUDY ON SOFT TISSUE SARCOMA
Phase Ⅲ data to be presented in a Soft Tissue Sarcoma oral session at ASCO
May 29, 2015
EISAI SUBMITS APPLICATIONS FOR REEVALUATION OF EFFICACY AND PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NEUZYM® BASED ON RESULTS OF REEVALUATION STUDIES
May 29, 2015
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis
May 27, 2015
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
May 27, 2015
EISAI RECEIVES POSITIVE CHMP OPINION ON INDICATION EXPANSION FOR ANTIEPILEPTIC AGENT FYCOMPA® (PERAMPANEL) AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
May 21, 2015
EISAI TO PROMOTE CLINICAL TRIAL DATA DISCLOSURE FOR THE ADVANCEMENT OF SCIENCE AND MEDICINE
May 20, 2015
EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER IN JAPAN
May 14, 2015
Notification Regarding Partial Amendment to the Articles of Incorporation
May 14, 2015
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 51ST ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW CLINICAL DATA ON HALAVEN® (ERIBULIN) IN SOFT TISSUE SARCOMA AND ON LENVIMA® (LENVATINIB) IN RENAL CELL CARCINOMA
April 27, 2015
EISAI AND NIHON MEDI-PHYSICS ENTER COLLABORATION AGREEMENT TO CONTRIBUTE TO DIAGNOSIS AND TREATMENT OF DEMENTIA WITH LEWY BODIES
April 24, 2015
EISAI COMMENCES BUSINESS IN MEXICO, AIMS TO EXPAND CONTRIBUTION TO PATIENTS IN LATIN AMERICA
ANTICANCER AGENTS HALAVEN® AND GLIADEL® NEWLY LAUNCHED
April 13, 2015
EISAI AND GENOMICS PLC TO COLLABORATE IN ANALYSES OF LARGE-SCALE GENOTYPE/PHENOTYPE DATA TO INFORM DRUG DEVELOPMENT
April 3, 2015
NIIGATA UNIVERSITY AND EISAI PRESENT RESULTS OF JOINT RESEARCH IN U.S. ACADEMIC JOURNAL
MEASURING COGNITIVE DECLINE IN PATIENTS WITH ALZHEIMER'S DISEASE USING BLOOD-BASED BIOMARKERS
March 30, 2015
EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
CHMP Opinion Based on Positive SELECT Study Data
March 26, 2015
EISAI RECEIVES APPROVAL IN JAPAN FOR ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER
March 12, 2015
STATEMENT REGARDING CHANGES TO STRATEGIC PARTNERSHIP WITH EPIZYME, INC. TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTICANCER THERAPIES TARGETING EZH2 EPIGENETIC ENZYME
March 5, 2015
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored
March 3, 2015
CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT®
March 2, 2015
EISAI LAUNCHES ANTICANCER AGENT LENVIMA™ IN THE UNITED STATES
FIRST COUNTRY IN THE WORLD TO GAIN ACCESS TO NEW TREATMENT OPTION
February 25, 2015
EISAI TO ESTABLISH ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
February 25, 2015
PHASE Ⅲ TRIAL OF ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA SHOWS OVERALL SURVIVAL BENEFIT IN PRIMARY ENDPOINT
February 24, 2015
ADDITIONAL EXPLORATORY ANALYSIS OF PHASE Ⅱ TRIAL SUGGESTS ANTICANCER AGENT LENVATINIB EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
February 24, 2015
EISAI LAUNCHES PROTON PUMP INHIBITOR PARIET® TABLETS 5 MG IN JAPAN
February 19, 2015
EISAI RECEIVES APPROVAL IN JAPAN FOR FINE GRANULE FORMULATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS
February 16, 2015
U.S. FDA APPROVES ANTICANCER AGENT LENVIMA™ (LENVATINIB MESYLATE) AS TREATMENT FOR RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 16, 2015
EISAI RECEIVES APPROVAL OF ANTIEPILEPTIC DRUG BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT FOR PEDIATRIC PATIENTS IN THE UNITED STATES
U.S. PATENT EXCLUSIVITY EXTENDED BY SIX MONTHS
February 12, 2015
ANTICANCER AGENT LENVATINIB PHASE Ⅲ TRIAL RESULTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE
SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL SHOWN IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 5, 2015
NOTICE REGARDING EISAI'S OPTIONS RELATING TO BIOGEN IDEC'S INVESTIGATIONAL ANTI-ALZHEIMER'S DISEASE TREATMENTS
January 30, 2015
PHASE Ⅱ TRIAL OF ANTICANCER AGENT LENVATINIB IN RENAL CELL CARCINOMA MEETS PRIMARY ENDPOINT
January 30, 2015
Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2015
January 26, 2015
EISAI AND AJINOMOTO PHARMACEUTICALS LAUNCH BRANCHED-CHAIN AMINO ACID FORMULA LIVAMIN® ORAL GRANULES IN THE PHILIPPINES
January 23, 2015
EISAI LISTED IN GLOBAL 100 SUSTAINABILITY INDEX FOR THIRD CONSECUTIVE YEAR
ONLY COMPANY FROM JAPAN INCLUDED IN 2015
January 5, 2015
PHASE Ⅲ TRIAL OF ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY PARTIAL-ONSET SEIZURES CONDUCTED IN ASIA INCLUDING JAPAN AND CHINA MEETS PRIMARY ENDPOINT
